NEW YORK, August 10, 2018 – Levi & Korsinsky announces an investigation concerning the sale of OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQGS: OVAS). Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of OvaScience to Millendo Therapeutics, Inc. Under the terms of the transaction, OvaScience shareholders will receive shares in the combined entity for each share of OvaScience they own, and will own approximately 20% of the combined company. Per a press release issued on August 9, 2018, shares will be allocated “subject to adjustment based on OvaScience’s net cash balance at the time of closing and the amount of any additional financing consummated by Millendo at or before the closing of the merger.” To learn more about the OVAS merger and your rights, go to: http://www.zlk.com/mna/ovascience-inc or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The OvaScience merger investigation concerns whether the Board of OvaScience breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Millendo Therapeutics, Inc. is underpaying for OvaScience shares, thus unlawfully harming OvaScience shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.